Clinical Trials Browser

Interventional × Rifaximin × 1 year × Clear all

NCT04249622 2025-09-16

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

Phase 2 Terminated

20 enrolled 13 charts

Anatomic Stage I Breast Cancer AJCC v8

NCT03820817 2025-04-20

Rifaximin in Patients With Monoclonal Gammopathy

Phase 1 Active not recruiting

Waldenstrom Macroglobulinemia, Paraproteinemias